
Neurogene Inc (NGNE) Stock Forecast & Price Target
Neurogene Inc (NGNE) Analyst Ratings
Bulls say
Neurogene is poised for success with its drug candidates, NGN-401 and NGN-101, which have shown durable and multi-domain improvements in clinical trials with no regression, setting itself apart from competitors who only focus on single-skill gains. With the support of key opinion leaders and a clear responder definition, Neurogene is likely to see success in securing ICV reimbursement, and its runway through 1Q28 provides a promising financial outlook.
Bears say
Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. While the company's proprietary EXACT technology may hold promise, the fact that its product pipeline is limited to just two candidates puts it at risk for lack of diversification. In addition, the high cost of developing and obtaining approvals for genetic medicines may pose challenges for Neurogene's financial success.
This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.
Neurogene Inc (NGNE) Analyst Forecast & Price Prediction
Start investing in Neurogene Inc (NGNE)
Order type
Buy in
Order amount
Est. shares
0 shares